LOGIN  |  REGISTER
Viking Therapeutics

Latest Leadership Change News

Myomo Announces Upcoming Changes to its Board of Directors

April 10
Last Trade: 4.43 0.14 3.26

BURLINGTON, Mass. / Apr 10, 2025 / Business Wire / Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that directors Amy Knapp and Yitzchak Jacobovitz have informed the board they will not stand for re-election as Class II directors. Ms. Knapp has been a director since...Read more


Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

April 10
Last Trade: 4.38 -1.00 -18.62

VANCOUVER & DALLAS / Apr 10, 2025 / Business Wire / Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology...Read more


Helix BioPharma Appoints Dr. Thomas Mehrling as Chief Executive Officer to Drive Ambitious Clinical Development Plan

April 10
Last Trade: 0.77 -0.02 -2.53

April 10, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP”, OTC PINK: “HBPCD”, FRANKFURT: “HBP0”) (“Helix” or the “Company”), a clinical-stage oncology company shaping a near future where today’s hard-to-treat cancers are vincible, today announced the appointment of Thomas Mehrling, MD, PhD as Chief Executive Officer (“CEO”) of the Company. A sharpening of Helix’s leadership structure, outgoing CEO, Jacek Antas,...Read more


Calidi Biotherapeutics Announces Appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor

April 10
Last Trade: 0.42 0.01 2.94

SAN DIEGO, April 10, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced the appointment of Guy Travis Clifton, MD as Chief Medical Officer, Consultant and Advisor. “With our recently filed IND for a company sponsored, dose escalation trial of CLD-201 in adult patients with solid...Read more


GE HealthCare names Jeannette Bankes president and CEO, Patient Care Solutions

April 9
Last Trade: 62.81 0.53 0.85

CHICAGO / Apr 09, 2025 / Business Wire / GE HealthCare (Nasdaq: GEHC), a leading global healthcare solutions provider, announced the appointment of Jeannette Bankes as president and CEO, Patient Care Solutions, effective May 1, 2025. Peter Arduini, president and CEO, GE HealthCare, said, “Jeannette is a proven leader who has diverse and deep experience at publicly traded companies in the healthcare industry. We proudly welcome her to the...Read more


Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer

April 9
Last Trade: 24.12 1.72 7.68

WATERTOWN, Mass., April 09, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Noah Goodman, M.B.A., as Chief Business Officer. Mr. Goodman brings a wealth of diverse experience in the life sciences industry to Kymera and will lead business development...Read more


Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors

April 9
Last Trade: 2.98 0.11 3.83

SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced today that Richard van den Broek, managing partner at HSMR Advisors, has been appointed to the Company’s board of directors. Mr. van den Broek has more than 30 years of experience in the life sciences industry as an investor, biotechnology equity research analyst and board...Read more


Royalty Pharma Appoints Vlad Coric, M.D. to the Company’s Board of Directors

April 8
Last Trade: 31.95 0.74 2.37

NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Vlad Coric, M.D. to the company’s Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer of Biohaven, a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and...Read more


iCAD Expands Executive Leadership with Appointment of Mark Koeniguer as Chief Commercial Officer

April 8
Last Trade: 1.78 0.11 6.59

NASHUA, N.H., April 08, 2025 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD) ("iCAD" or the "Company") a global leader on a mission to create a world where cancer can’t hide by providing clinically proven AI-powered breast health solutions, today announced the appointment of Mark Koeniguer as Chief Commercial Officer (CCO), to lead the next phase of global growth for iCAD. As CCO at iCAD, Koeniguer will assume responsibilities for revenue...Read more


VentriPoint Diagnostics Appoints Nicolas Coutin to Oversee Clinical Affairs

April 8
Last Trade: 0.13 -0.005 -3.70

Toronto, Ontario – TheNewswire - April 8, 2025 – Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT; OTC:VPTDF) today announced that it has appointed Nic Coutin, PhD. to oversee Clinical Affairs. In this role he will be providing leadership to the Company’s ongoing research, translational science, and clinical studies. Nicolas will report directly to Hugh MacNaught, President and CEO. Dr. Coutin was part of the...Read more


Aspira Women's Health Appoints Three New Directors, Executes $2.0 Million Equity Purchase Agreement

April 8
Last Trade: 0.10 0.0023 2.43

New Directors Bring Extensive Commercial Healthcare Relationships to Expand Business Development Opportunities. AUSTIN, TX / ACCESS Newswire / April 8, 2025 / Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the appointment of three new Directors to its Board of Directors. These...Read more


Krystal Biotech: Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer

April 7
Last Trade: 165.00 4.35 2.71

PITTSBURGH, April 07, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. (“Jeune”), a wholly owned subsidiary of Krystal Biotech, Inc. (“Krystal”) (NASDAQ: KRYS) leveraging Krystal’s clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Marc Forth as Chief Executive Officer (CEO), effective today. A veteran of the healthcare industry, Mr. Forth has over...Read more


Amarin Appoints JEC Capital Partners’ Michael Torok to Board of Directors

April 7
Last Trade: 9.30 8.85 1,959.80

DUBLIN, Ireland and BRIDGEWATER, N.J., April 07, 2025 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the appointment of Michael Torok, Co-Founder and Managing Director of investment firm JEC Capital Partners, as a member of the Board of Directors, effective immediately. “On behalf of the board, I welcome Michael. His financial expertise, experience on other boards and, as a fellow shareholder, his shared...Read more


Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors

April 7
Last Trade: 12.02 0.61 5.35

Mr. Ajer was most recently Chief Commercial Officer at BioMarin  WALTHAM, Mass. / Apr 07, 2025 / Business Wire / Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Jeff Ajer to its Board of Directors. Mr. Ajer has more than 25 years of experience driving commercialization...Read more


Treace Medical Concepts Announces Upcoming Board Chair Transition

April 7
Last Trade: 6.74 -0.25 -3.58

PONTE VEDRA, Fla., April 07, 2025 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. ("Treace" or the "Company") (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced that its Board of Directors has appointed John. T. Treace, Chief Executive Officer and Founder of Treace,...Read more


MBX Biosciences Appoints Veteran Pharmaceutical Executive Steve Hoerter to Board of Directors

April 7
Last Trade: 7.41 1.14 18.18

CARMEL, Ind., April 07, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced the appointment of Steve Hoerter as an independent director to the Company’s Board of Directors. Mr. Hoerter brings over three decades of pharmaceutical...Read more


Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer

April 7
Last Trade: 1.62 -3.74 -69.78

Distinguished, highly accomplished clinician with stellar track record of successfully leading numerous registrational trials through global regulatory approvals, and establishing new standards of care in gynecological oncology over the past decades Will lead all clinical development -- including the ongoing ACR-368 Phase 2b registrational-intent trial in endometrial cancer towards regulatory submission and potential approval, and the...Read more


Neurocrine Biosciences Appoints Dr. Sanjay Keswani as Chief Medical Officer

April 4
Last Trade: 90.87 0.15 0.17

Accomplished physician-scientist brings more than 20 years of industry leadership experience and broad R&D expertise in multiple therapeutic areas  SAN DIEGO, April 4, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Sanjay Keswani, M.D., to the company's executive management team as Chief Medical Officer (CMO) effective June 2, 2025. Dr. Keswani, an accomplished...Read more


Telo Genomics Announces Appointment of John Farlinger to Its Board of Directors

April 4
Last Trade: 0.10 0.01 11.11

Toronto, Ontario--(Newsfile Corp. - April 4, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce that John Farlinger has joined the Company's Board of Directors. Mr. Farlinger will also serve as Chair of the Company's audit committee. Mr. Farlinger is...Read more


Telix Pharmaceuticals: Anne Whitaker Appointed as Non-Executive Director

April 3
Last Trade: 16.65 0.25 1.52

MELBOURNE, Australia and INDIANAPOLIS, April 04, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces the appointment of Anne Whitaker as a Non-Executive Director (NED) based in the United States, effective 7 April 20251. Ms. Whitaker is a seasoned healthcare leader and advisor with over 30 years’ global corporate experience spanning large pharmaceutical, biotech and...Read more


Ardent Health Appoints Robert DeMichiei to Board of Directors

April 3
Last Trade: 11.78 -0.33 -2.73

BRENTWOOD, Tenn. / Apr 03, 2025 / Business Wire / Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced the appointment of Robert A. DeMichiei to its board of directors. A seasoned leader with over 30 years of experience in financial strategy, healthcare operations, and board governance, Mr. DeMichiei served as executive vice president and chief financial...Read more


Harmony Biosciences Appoints Biotech Leader Ron Philip to Its Board of Directors

April 3
Last Trade: 29.17 0.18 0.62

PLYMOUTH MEETING, Pa. / Apr 03, 2025 / Business Wire / Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the appointment of Ron Philip to the Company's Board of Directors. Ron Philip is the President and Chief Executive Officer of Orbital Therapeutics. Ron has 30 years of experience building companies, leading organizational growth, and guiding teams through the development, regulatory approval, and commercialization of...Read more


PanGenomic Health Announces Management Change

April 3
Last Trade: 0.20 0.00 0.00

Vancouver, British Columbia, Canada – TheNewswire - April 3, 2025 – PanGenomic Health Inc. ("PanGenomic Health" or the "Company") (CSE: NARA) announces the resignation of Tammy Gillis as CFO of the Company. Ms. Gillis will continue to act as a financial consultant to the Company, and in particular, assist with completion of the year end audit process for the last fiscal year. Current director Francisco Kent Carasquero will assume the role...Read more


Aura Biosciences Announces Appointment of Teresa Bitetti to Board of Directors

April 2
Last Trade: 5.30 0.33 6.64

BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the appointment of Teresa Bitetti, President of the Global Oncology Business Unit at Takeda, to the Company’s Board of Directors, effective March 31, 2025. “I am pleased to welcome Teresa to our Board of Directors,”...Read more


Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors

April 2
Last Trade: 0.48 0.04 9.35

WEST CHESTER, Pa., April 02, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or the “Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Gavin Corcoran, M.D. to its Board of Directors. “We are pleased to welcome Dr. Gavin Corcoran to our Board of Directors,” said Jayson Rieger, Ph.D., MBA, President and...Read more


HCA Healthcare Names Monica Cintado as Senior Vice President of Development

April 1
Last Trade: 333.37 -1.62 -0.48

Joseph A. Sowell to retire after more than 15 years of service NASHVILLE, Tenn. / Apr 01, 2025 / Business Wire / HCA Healthcare, Inc. (NYSE:HCA), one of the nation’s leading healthcare providers, today announced that Monica Cintado has been appointed as senior vice president of development, effective immediately. In this role, Cintado will lead HCA Healthcare’s enterprise development strategy, overseeing mergers, acquisitions,...Read more


Tony Zook Assumes Role as Chief Executive Officer of NeoGenomics

April 1
Last Trade: 9.32 0.42 4.72

FT. MYERS, Fla. / Apr 01, 2025 / Business Wire / NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ: NEO), a leading oncology testing services company, today announced that Tony Zook has officially assumed the role of Chief Executive Officer. A member of the company’s Board of Directors since 2023, Zook brings more than three decades of experience across diagnostics and biopharma, along with a proven track record of leadership in...Read more


Phathom Pharmaceuticals Announces Leadership Succession

April 1
Last Trade: 4.88 0.77 18.73

FLORHAM PARK, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that Steven Basta has been appointed President and Chief Executive Officer and a member of the Board of Directors, effective immediately. Mr. Basta succeeds Terrie Curran, who is stepping down as...Read more


Esperion Appoints Robert E. Hoffman to Board of Directors

April 1
Last Trade: 1.02 0.06 6.25

Veteran Industry Executive Brings Decades of Financial and Leadership Experience  ANN ARBOR, Mich., April 01, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Robert E. Hoffman as an independent director, effective immediately, and he will also serve as Chairperson of the Audit Committee effective May 29, 2025. In addition, the Company announced that Nicole Vitullo and Antonio M. Gotto, Jr.,...Read more


Codexis Appoints Cynthia Collins to Board of Directors

April 1
Last Trade: 2.33 0.08 3.73

REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the appointment of Cynthia Collins to the Company’s Board of Directors. “I am thrilled to welcome Cindy to our Board,” said Stephen Dilly, MBBS, PhD, Chairman and Chief Executive Officer at Codexis. “She has been at the forefront of...Read more


Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President

April 1
Last Trade: 11.61 0.29 2.56

SAN DIEGO, April 1, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with two programs in clinical-stage development, today announced the departure of Dr. Brendan Eckelman, co-founder and Chief Scientific Officer (CSO) and the appointments of Dr. Carlos Bais and David Matly to CSO and President, respectively. Dr. Eckelman leaves the Company to establish...Read more


Korro Bio Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer

April 1
Last Trade: 12.90 -0.07 -0.54

CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company focused on developing a new class of genetic medicines based on editing RNA for both rare and highly prevalent diseases, announced today the appointment of Loïc Vincent, Ph.D., as the Company’s Chief Scientific Officer. “We are excited to welcome Dr. Vincent, whose extensive drug development experience...Read more


InfuSystem Announces CEO Transition; Carrie Lachance to Become Chief Executive Officer

April 1
Last Trade: 4.98 0.07 1.43

The Company Reaffirms Full Year 2025 Guidance: Revenue Growth of 8-10% and Adjusted EBITDA (non-GAAP) margin greater than 18.8% ROCHESTER HILLS, Mich. / Apr 01, 2025 / Business Wire / InfuSystem Holdings, Inc. (NYSE American: INFU) (“InfuSystem” or the “Company”), a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, today announced that...Read more


Journey Medical Appoints Ramsey Alloush as Chief Operating Officer

April 1
Last Trade: 6.03 -0.03 -0.50

SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical” or the “Company”), a commercial-stage pharmaceutical company that primarily focuses on the selling and marketing of U.S. Food and Drug Administration (“FDA”) approved prescription pharmaceutical products for the treatment of dermatological conditions, is pleased to announce the promotion of Ramsey Alloush, currently General...Read more


Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

April 1
Last Trade: 0.97 0.04 4.30

Appointment of seven recognized experts is validating for Ventyx’s NLRP3 Program AD/PD™ 2025 provides helpful insights on potential next steps in Parkinson’s disease SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, today...Read more


Climb Bio Appoints Seasoned Biotech Leaders to Board of Directors

April 1
Last Trade: 3.01 0.00 0.00

WELLESLEY HILLS, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM) today announced the appointments of biotech industry veterans Kim Cobleigh Drapkin, CPA, and Bo Cumbo to its Board of Directors. Ms. Drapkin will assume the role of Audit Committee Chair, and Mr. Cumbo will assume the role of Compensation Committee Chair. “We are delighted to welcome Kim and Bo to our Board of Directors at Climb Bio,” said Aoife...Read more


Ardent Health Announces Appointment of Chief Operating Officer and Senior Leadership Promotions

March 31
Last Trade: 11.78 -0.33 -2.73

BRENTWOOD, Tenn. / Mar 31, 2025 / Business Wire / Ardent Health (NYSE: ARDT), a leading provider of healthcare in growing mid-sized urban communities across the U.S., today announced the appointment of Dave Caspers as chief operating officer. In this new role, Caspers will oversee operations across Ardent Health, which includes 30 hospitals and 280 sites of care in six states. He will be responsible for executing on strategic growth...Read more


Repare Therapeutics Announces Leadership Transitions

March 31
Last Trade: 0.90 0.00 0.00

Steve Forte, Executive Vice President and Chief Financial Officer, appointed as President, Chief Executive Officer and Director Lloyd M. Segal has resigned as President, Chief Executive Officer and Director to pursue other opportunities CAMBRIDGE, Mass. & MONTREAL / Mar 31, 2025 / Business Wire / Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today...Read more


PepGen Announces Appointment of Two New Directors to its Board

March 31
Last Trade: 1.13 -0.04 -3.42

BOSTON / Mar 31, 2025 / Business Wire / PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced the appointments of Lisa Wyman and Mitchell H. Finer, PhD, to its Board of Directors. Ms. Wyman and Dr. Finer are industry veterans, each bringing decades of executive...Read more


BetterLife Pharma Appoints New Director

March 31
Last Trade: 0.09 0.00 0.00

VANCOUVER, British Columbia, March 31, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB : BETRF / FRA: NPAU), an emerging biotech company, is pleased to announce it has appointed Dr. Steven Sangha to its Board of Directors. Dr. Sangha has over 25 years of business experience, including investment banking, business development and asset management. His extensive background with public...Read more


Alector Provides Executive Leadership Update

March 28
Last Trade: 0.95 0.05 5.05

Giacomo Salvadore, M.D., appointed Chief Medical Officer Gary Romano, M.D., Ph.D., to transition from Chief Medical Officer role SOUTH SAN FRANCISCO, Calif., March 28, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a late-stage clinical biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that Gary Romano, M.D., Ph.D., has made the decision to...Read more


Traws Pharma Announces Management Updates

March 28
Last Trade: 2.00 0.25 14.29

Werner Cautreels, PhD, to retire as CEO, while continuing as a Board Member Iain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced...Read more


Becton Dickinson Names Gregory J. Hayes to Board of Directors

March 27
Last Trade: 201.78 2.66 1.34

FRANKLIN LAKES, N.J., March 27, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced the appointment of Gregory J. Hayes to its board of directors, effective March 26, 2025. Hayes, 64, is currently the executive chairman of the board of directors of RTX Corporation, the world's largest aerospace and defense company. He brings more than 30 years of...Read more


Bicycle Therapeutics Announces New Board and Key Clinical Leadership Appointments

March 27
Last Trade: 6.70 0.17 2.60

Felix J. Baker, Ph.D., to become chairman of Board of Directors Alessandro Riva, M.D., joins Board of Directors and Fabrice André, M.D., Ph.D., joins Clinical Advisory Board Eric Westin, M.D., promoted to chief medical officer and Jim MacDonald-Clink promoted to senior vice president, head of business development CAMBRIDGE, England & BOSTON / Mar 27, 2025 / Business Wire / Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical...Read more


TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access

March 27
Last Trade: 1.24 0.11 9.73

WALTHAM, Mass., March 27, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the appointment of Stephen Camiolo as Senior Vice President, Market Access. Mr. Camiolo brings to TScan over 25 years of experience in market access, reimbursement,...Read more


Beta Bionics Announces Board Appointment of Gerard Michel

March 27
Last Trade: 0 0.00 0.00

IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced the appointment of Gerard Michel as an independent member of its board of directors, effective March 26, 2025. Mr. Michel is Chief Executive Officer of Delcath Systems (Nasdaq: DCTH), a commercial-stage interventional oncology company. “We are excited to...Read more


Rezolute Announces Appointment of Rare Disease Commercial Leader Erik Harris to its Board of Directors

March 26
Last Trade: 2.47 0.00 0.00

REDWOOD CITY, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, announced the appointment of Erik Harris to its Board of Directors, effective immediately. Mr. Harris, who currently serves as Chief Commercial Officer and Executive Vice President at Ultragenyx, brings more than 20 years...Read more


Invivyd Appoints Ajay Royan, Founder of Mithril Capital, to its Board of Directors

March 26
Last Trade: 0.55 0.04 8.71

WALTHAM, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) is pleased to announce the appointment of Ajay Royan to its Board of Directors. Mr. Royan is a venture capitalist focused on transformational companies that have solved critical problems in healthcare, technology, and energy. Mr. Royan’s investment firm, Mithril, is a significant long-term holder of Invivyd stock, and Mr. Royan led the 2022 shareholder...Read more


Avalo Therapeutics Appoints Michael Heffernan as Chairman of the Board

March 26
Last Trade: 4.90 -0.04 -0.81

WAYNE, Pa. and ROCKVILLE, Md., March 26, 2025 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical-stage biotechnology company dedicated to treating immune dysregulation, today announced the appointment of Michael Heffernan as Chairman of the Board of Directors (“Board”). Mr. Heffernan will succeed Dr. Garry Neil as Chairman of the Board. Dr. Neil will continue as a Board member and Chief Executive Officer (CEO) of the...Read more


Defence Therapeutics Announces US Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Defence's Management Team as Chief Operating Officer

March 26
Last Trade: 0.93 0.03 3.33

Montreal, Quebec--(Newsfile Corp. - March 26, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing radiopharmaceuticals and ADC products using its proprietary platform and drug delivery technologies in addition to novel immune-oncology vaccines, is pleased to announce that Dr. Elias Theodorou is joining the management team as the Chief...Read more


Mydecine Innovations Announces Changes To Board And Management

March 26
Last Trade: 0.003 -0.0006 -16.67

Vancouver, British Columbia, March 26, 2025 — TheNewswire - Mydecine Innovations Group Inc. (the “Company”) (CSE: MYCO) (FSE: 0NF0) (OTC: MYCOF) is pleased to announce the appointments of Mr. Peter Field to its board of directors, effective March 18, 2025. Mr. Field is a seasoned entrepreneur with over 30 years of experience in business development, product innovation, and leadership. Based in Vancouver, he has been involved in ventures...Read more


Dexcom Appoints Jon Coleman as Chief Commercial Officer

March 25
Last Trade: 66.14 -1.16 -1.72

SAN DIEGO / Mar 25, 2025 / Business Wire / DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom’s global commercial organization, including global sales, marketing and customer experience. Mr. Coleman joins Dexcom with more than 30 years of global commercial leadership experience...Read more


Illumina Board of Directors elects Dr. Scott Gottlieb Chair, Keith Meister to join Board of Directors

March 25
Last Trade: 74.78 3.52 4.94

Stephen MacMillan to retire from the Board SAN DIEGO, March 25, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced changes to its Board of Directors. Scott Gottlieb, MD, has been elected non-executive Chair of Illumina's Board. Dr. Gottlieb has served on the Board of Directors since 2020. Additionally, Keith Meister, founder, Managing Partner, and Chief...Read more


Biomea Fusion Announces Leadership Transition

March 25
Last Trade: 1.75 0.02 1.16

Board member Mick Hitchcock, named interim CEO replacing Thomas Butler. COO and President Ramses Erdtmann continuing at Biomea in current role. REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) --  Biomea Fusion, Inc. (“Biomea,” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, announced today an executive leadership change to help ensure the company realizes its full potential...Read more


Axogen Announces Appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy, and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

March 24
Last Trade: 15.89 0.09 0.57

ALACHUA, Fla. and TAMPA, Fla., March 24, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy. Mr. Ditto will report to Michael Dale, President, and Chief Executive Officer, and will lead the development of the...Read more


Vicarious Surgical Announces President Transition to Board Member Role

March 24
Last Trade: 5.32 -0.11 -2.03

WALTHAM, Mass. / Mar 24, 2025 / Business Wire / Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that Company President, Randy Clark, will transition to Board Member, effective April 25, 2025, pending customary conflict checks. As President, Mr. Clark directed critical business...Read more


Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors

March 20
Last Trade: 59.15 -10.18 -14.68

Mr. Galligan and Ms. Myers bring decades of experience to the company board  Derek Yoon steps down from the Board of Directors  REDWOOD CITY, Calif. / Mar 20, 2025 / Business Wire / Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointments of Andrew Galligan and...Read more


Precision Optics Appoints Joseph P. Pellegrino, Jr. to Board of Directors

March 20
Last Trade: 82.82 1.46 1.79

GARDNER, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ: POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Joseph P. “JJ” Pellegrino, Jr. to its Board of Directors. Mr. Pellegrino, who will also serve as Chairman of the Board’s Audit Committee, brings decades of operational and...Read more


Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer

March 20
Last Trade: 1.07 -0.04 -3.60

Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio of products spanning both solid and hematological malignancies that have total annual sales of $1B Held several executive leadership roles at Amgen, Pfizer, and Johnson & Johnson across multiple brands including Kyprolis®, Vectibix®, Neulasta®, XGEVA®, Repatha®, and ELIQUIS® Current President and CEO, Samir...Read more


Sera Prognostics Announces Appointment Of Jeff Elliott To Its Board; Ryan Trimble And Marcus Wilson To Step Down

March 19
Last Trade: 3.25 0.14 4.50

SALT LAKE CITY, March 19, 2025 /PRNewswire/ -- Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that Jeff Elliott will join its Board of Directors on March 20, 2025. The Company further announced that Ryan Trimble—after 14 years serving Sera, its customers and its...Read more


Recursion Bolsters Board of Directors with Former FDA Principal Deputy Commissioner Dr. Namandjé Bumpus and Mammoth Biosciences COO and CFO Elaine Sun

March 18
Last Trade: 5.75 1.24 27.49

Salt Lake City, UT, March 18, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that Namandjé Bumpus, Ph.D, and Elaine Sun have been appointed to Recursion’s Board of Directors, effective as of March 15th.“I am delighted to welcome Elaine and Namandjé to Recursion’s Board,” said Chris Gibson, Ph.D., Recursion Co-Founder and CEO. “As the...Read more


NeoGenomics Appoints Warren Stone as President & Chief Operating Officer

March 18
Last Trade: 9.32 0.42 4.72

Stone to drive lab operations, data solutions division and enterprise operations functions in addition to existing commercial responsibilities Leadership team aligned to support long term growth, profitability, and operational execution FT. MYERS, Fla. / Mar 18, 2025 / Business Wire / NeoGenomics, Inc. (“NeoGenomics” or the “Company”) (NASDAQ:NEO), a leading provider of oncology diagnostic solutions that enable precision medicine,...Read more


SIGA Technologies Appoints Retired General John M. Keane to its Board of Directors

March 18
Last Trade: 5.96 -0.22 -3.56

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, announced today the appointment of Retired United States Army General John “Jack” Keane to its Board of Directors, effective immediately. General Keane, a retired four-star general, completed 37 years of public service in December 2003, culminating with his appointment as acting Chief of Staff and Vice...Read more


Stoke Therapeutics Announces CEO Transition

March 18
Last Trade: 7.02 0.50 7.67

Edward M. Kaye, M.D., to Step Down as Chief Executive Officer Director Ian F. Smith Appointed Interim Chief Executive Officer Arthur Tzianabos Appointed Interim Executive Chairman of the Board Board of Directors Initiates Search for Permanent Chief Executive Officer BEDFORD, Mass. / Mar 18, 2025 / Business Wire / Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by...Read more


CAMP4 Therapeutics Appoints Multiple Industry Veterans to its Board of Directors

March 18
Last Trade: 2.00 -0.10 -4.76

With decades of experience in pharmaceutical development and extensive genetic medicine expertise, Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP, will provide strategic guidance for CAMP4’s multiple drug development efforts CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting antisense...Read more


Elanco Animal Health Announces Changes to Board of Directors; Signs Research Agreement to Explore Novel Therapies for Chronic Kidney Disease and Life Extension in Pets

March 17
Last Trade: 8.60 -0.11 -1.26

GREENFIELD, Ind., March 17, 2025 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced changes to its Board of Directors that will reduce the Board size to 11 directors by the 2025 Annual Meeting of Shareholders: John P. (JP) Bilbrey, Kathy Turner and Craig Wallace have each informed the Board they will not stand for re-election at the conclusion of their terms at the 2025 Annual Meeting of...Read more


Collegium Pharmaceutical Announces Updates to its Board of Directors and Executive Leadership Team

March 17
Last Trade: 26.30 1.63 6.61

Gino Santini Appointed as Chairman of the Board, Michael Heffernan, Founder and Chairman and Gwen A. Melincoff, Board Member to Retire from Board – Dr. Carlos Paya Nominated to Board of Directors  New Executives Appointed to Leadership Team; David Dieter, as Executive Vice President, General Counsel, Jane Gonnerman as Executive Vice President, Strategy and Corporate Development and Dean J. Patras, as Chief People...Read more


STAAR Surgical Announces Realignment of Leadership Structure

March 17
Last Trade: 16.79 1.22 7.84

Warren Foust Named President and Chief Operating Officer Magda Michna, PhD Appointed Chief Development Officer Deborah Andrews, STAAR’s Chief Financial Officer from 2017- 2020, to serve as Interim Chief Financial Officer Patrick F. Williams Steps Down as Chief Financial Officer Keith Holliday Retires as Chief Technology Officer LAKE FOREST, Calif. / Mar 17, 2025 / Business Wire / STAAR Surgical Company (NASDAQ: STAA), the global...Read more


Avanos Medical Announces Appointment of David Pacitti as Chief Executive Officer

March 17
Last Trade: 12.47 0.04 0.32

ALPHARETTA, Ga., March 17, 2025 /PRNewswire/ -- Avanos Medical, Inc. (NYSE: AVNS), a leading medical technology company, today announced the appointment of David Pacitti as its new chief executive officer, effective April 14, 2025. Pacitti joins Avanos with a distinguished career in the healthcare sector, most recently serving as president of Siemens Medical Solutions USA, Inc. and Head of the Americas, Siemens Healthineers. In this...Read more


GoodRx Appoints Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement

March 17
Last Trade: 4.42 0.10 2.31

Accomplished healthcare executives will work to drive growth, strengthen industry partnerships, and enhance pharmacy innovation at GoodRx SANTA MONICA, Calif. / Mar 17, 2025 / Business Wire / GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., today announced the appointment of Aaron Crittenden as President of Rx Marketplace and Scott Pope, PharmD, as Chief Pharmacy Officer and Head of Clinical Engagement,...Read more


Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors

March 17
Last Trade: 4.01 -0.12 -2.91

SAN DIEGO / Mar 17, 2025 / Business Wire / Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the appointment of Diego Miralles, M.D. as a member of its board of directors, effective March 14, 2025. “We are excited to welcome Diego to our...Read more


Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer

March 17
Last Trade: 7.93 1.15 16.96

Dr. von Moltke brings over 30 years of deep drug development experience and a proven track record of clinical and regulatory success at both large and emerging global biopharmaceutical companies WALTHAM, Mass., March 17, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of...Read more


Evome Medical Technologies Appoints Michael Dalsin as Chairman of the Board of Directors; Increases Size of Board to Six

March 17
Last Trade: 0.005 0.00 0.00

NEW YORK, March 17, 2025 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company”) (TSXV: EVMT) ‎announces the appointment of Michael Dalsin as Chairman of the Board of Directors. Kenneth Kashkin, MD will take the role of Vice-Chairman. Bill Garbarini will retain his role as COO while stepping off the Board of Directors. Chris Heath was also appointed as a new Director increasing the size of the Board of Directors from five to...Read more


Cigna announces leadership changes to accelerate the company's growth strategy

March 13
Last Trade: 330.19 2.92 0.89

Brian Evanko named President and Chief Operating Officer, The Cigna Group Ann Dennison named Executive Vice President and Chief Financial Officer, The Cigna Group Nicole Jones, Chief Administrative Officer and General Counsel, to assume oversight of Enterprise Marketing Eric Palmer, President and Chief Executive Officer of Evernorth Health Services, to depart The Cigna Group Reaffirms Full Year 2025 Financial Outlook BLOOMFIELD,...Read more


Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch., M.Med., Ph.D., to Its Board of Directors

March 13
Last Trade: 9.14 0.33 3.75

SAN FRANCISCO, March 13, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, announced today the appointment of Roy D. Baynes, MB.Bch., M.Med., Ph.D., to its board of directors. Dr. Baynes, who currently serves as executive vice president and chief medical officer of Eikon...Read more


Xencor Appoints Todd Simpson to Board of Directors

March 13
Last Trade: 8.54 0.62 7.83

PASADENA, Calif. / Mar 13, 2025 / Business Wire / Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced the appointment of Todd Simpson to its board of directors. Mr. Simpson has more than 40 years of experience in chief financial officer (CFO) roles at multiple biopharmaceutical companies and in public accounting. Most...Read more


ZimVie Announces Upcoming Changes to Company's Board of Directors

March 13
Last Trade: 9.15 0.08 0.88

PALM BEACH GARDENS, Fla., March 13, 2025 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental implant market, today announced upcoming changes to the Company's Board of Directors, including:  Non-Executive Chair David King will not stand for reelection as a director upon the expiration of his current term at the Company's annual meeting of shareholders on May 7, 2025. President and CEO Vafa...Read more


HLS Therapeutics Appoints Christine Elliott to its Board of Directors

March 13
Last Trade: 4.03 0.01 0.25

TORONTO, March 13, 2025 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that Christine Elliott has been appointed to the Company's Board of Directors (the "Board"), effective immediately. Ms. Elliott served as Ontario's Deputy Premier and Minister of Health from 2018 to 2022,...Read more


Senti Biosciences Appoints Feng Hsiung to Board of Directors

March 13
Last Trade: 3.26 0.38 13.19

SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio,” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it has appointed Feng Hsiung, an executive with extensive business, finance and investment experience, to the Senti Bio Board of Directors (the...Read more


Orthofix Medical Announces Appointment of Vickie Capps to Board of Directors

March 12
Last Trade: 13.67 -0.25 -1.80

LEWISVILLE, Texas / Mar 12, 2025 / Business Wire / Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the appointment of Vickie Capps to the Company's Board of Directors, effective March 11, 2025. “Vickie brings a wealth of experience to our Board at a pivotal stage for Orthofix,” said Michael Finegan, Chairman of Orthofix. “Her expertise in global business operations, strategic business...Read more


Telo Genomics Appoints Baechler Executive Chairman of The Board of Directors

March 12
Last Trade: 0.10 0.01 11.11

Toronto, Ontario--(Newsfile Corp. - March 12, 2025) - Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (the "Company" or "Telo Genomics") a leader in the development of diagnostic and prognostic tests for human disease through the analysis of chromosomal telomeres, is pleased to announce Mr. Guido Baechler, has assumed the role of Executive Chairman. In his expanded role, Mr. Baechler will provide more active strategic leadership, working...Read more


Shuttle Pharmaceuticals Announces Appointment of Christopher Cooper as Interim Co-CEO to Enhance Business Activities

March 12
Last Trade: 0.37 -0.05 -11.81

GAITHERSBURG, Md., March 12, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the appointment of Christopher Cooper as interim Co-Chief Executive Officer focused on enhancing the Company’s capital markets...Read more


Madrigal Pharmaceuticals Appoints Jacqualyn A. Fouse, Ph.D. to Its Board of Directors

March 11
Last Trade: 317.15 9.80 3.19

Fred Craves, Ph.D. to retire from Madrigal’s Board of Directors in July 2025 CONSHOHOCKEN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced it has appointed Jacqualyn (“Jackie”) Fouse, Ph.D. to its Board of Directors. Fred Craves, Ph.D. is retiring from...Read more


HealthStream Announces the Addition of Charles E. Beard, Jr. to the Board of Directors

March 11
Last Trade: 32.14 0.80 2.55

NASHVILLE, Tenn. / Mar 11, 2025 / Business Wire / HealthStream, Inc. (Nasdaq: HSTM), a leading healthcare technology platform company for workforce solutions, announced today that Charles E. Beard, Jr. has joined its Board of Directors and will serve as a member of the Audit Committee. Mr. Beard brings a wealth of experience from his more than 30-year career, where he has held several executive-level positions. Until his recent retirement...Read more


Novavax Announces Changes to Board of Directors

March 11
Last Trade: 5.86 0.43 7.92

James Young, PhD retires as Chair of the Board, Margaret McGlynn, RPh, appointed John Shiver, PhD appointed to board of directors GAITHERSBURG, Md., March 11, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that James Young, PhD, is retiring as Chair of the Board and Margaret McGlynn, RPh, has been appointed as his successor. The Company also appointed John Shiver, PhD, to its board as an independent...Read more


PureTech Health Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

March 11
Last Trade: 16.16 2.66 19.70

Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience BOSTON / Mar 11, 2025 / Business Wire / PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, (“Seaport”) a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric...Read more


Ocumetics Technology Announces Appointment of Michael L. Edwards to Board of Directors

March 11
Last Trade: 0.26 -0.02 -5.45

Calgary, Alberta – TheNewswire - March 11, 2025.  Ocumetics Technology Corp. (“Ocumetics” or the “Corporation”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce that it has appointed Michael Edwards, BBA, CPA, CA, CLU, to its Board of Directors. “We are thrilled to have Michael join our board of directors,” says Dr. Garth Webb, founder and Chairman of Ocumetics. “Michael has an...Read more


Matinas BioPharma Appoints Seasoned Biotech Leaders to Board of Directors

March 11
Last Trade: 0.54 0.03 5.32

BEDMINSTER, N.J., March 11, 2025 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) today announced the appointment of biotech industry veterans Keith Murphy and Edward Neugeboren to its Board of Directors as independent members, effective March 11, 2025 (the “Effective Date”). In addition, Matthew Wikler, M.D., and Natasha Giordano stepped down from the Board on the Effective Date. “We are thrilled to announce...Read more


Robert Musslewhite and Sudhakar Ramakrishna to join Cardinal Health Board of Directors

March 10
Last Trade: 131.77 2.89 2.24

DUBLIN, Ohio, March 10, 2025 /PRNewswire/ -- Cardinal Health (NYSE:CAH) announced today that its Board of Directors has elected Robert Musslewhite, former Chief Executive Officer of Definitive Healthcare Corp., and Sudhakar Ramakrishna, President and Chief Executive Officer of SolarWinds Corporation, as independent directors, effective March 7, 2025. With more than 20 years of leadership experience, including serving as CEO for two...Read more


Dexcom Appoints Renée Galá to Board of Directors

March 10
Last Trade: 66.14 -1.16 -1.72

SAN DIEGO / Mar 10, 2025 / Business Wire / DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Renée Galá to its Board of Directors, effective March 6, 2025. Ms. Galá is an accomplished executive with significant financial, strategic and operational leadership experience across the life sciences sector. She currently serves as President and Chief Operating Officer of Jazz Pharmaceuticals...Read more


Sign Up To Get Daily
Life Science News

Please review our Disclaimer and Privacy Policy before subscribing.

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE